Preclinically, Yong Shim et al. showed that alpelisib combined with an autophagy inhibitor yields synergistic antitumor effects in PIK3CA-mutant NSCLC in vitro and in vivo, motivating a planned phase I trial [55]. Here, PIK3CA is linked to non-small cell lung carcinoma.